FAQ on TransCode Therapeutics' 1-for-28 Reverse Stock Split

What is the purpose of TransCode Therapeutics’ reverse stock split?

The reverse stock split aims to increase the company’s per-share price to maintain compliance with Nasdaq’s minimum bid price requirement.

When will the reverse stock split take effect?

The reverse stock split will take effect on May 15, 2025, at 12:01 a.m. EDT.

How will the reverse stock split affect the number of outstanding shares?

Post-split, TransCode’s outstanding common stock will decrease from approximately 23.3 million to about 833,620 shares.

Will fractional shares be issued as part of the reverse stock split?

No fractional shares will be issued; instead, amounts will be rounded up to the nearest whole share.

Who is acting as the exchange agent for the reverse stock split?

Vstock Transfer LLC will act as the exchange agent for the reverse stock split.

What is the new CUSIP number for TransCode Therapeutics post-split?

The new CUSIP number will be 89357L 501.

Where can I find more information about TransCode Therapeutics and the reverse stock split?

More information is available in the company’s newsroom at https://ibn.fm/RNAZ and the full press release can be viewed at https://ibn.fm/j1haU.

What is TransCode Therapeutics’ focus in the biotech industry?

TransCode is a clinical-stage oncology company focused on treating metastatic disease through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform.

What is TransCode Therapeutics’ lead therapeutic candidate?

The Company’s lead therapeutic candidate is TTX-MC138, focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis.